Healthcare
AgomAb Therapeutics N.V. American Depositary Shares(AGMB)
Live Price
Offline$10.98
+8.71% today
Window Change
-13.45%
Window
Feb 6, 2026 โ Jun 24, 2026
- Market Cap
- $510.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -306.5%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 95 bars ยท Feb 6, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) is a Healthcare stock with a market cap of $510.00M and listed on NASDAQ. The stock last traded around $10.98 and down 13.4% across the available one-year price window (Feb 6, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -306.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -306.5%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AGMB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 25, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -306.5%, with operating margin around 0.0%.
Benchmark Edge
AGMB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AGMB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AGMB Max Drawdown
-40.72%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AGMB and SPY.
Company Overview
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ Global Market
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFรR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFรR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
- Leadership
- Tim Knotnerus
- IPO Date
- May 29, 2024
- Employees
- 57
- Street Address
- Posthoflei 1/6
- Mailing
- Antwerp, 2600
- Region
- Antwerp, BE
- Reporting Currency
- USD
- Investor Line
- 32 3 318 91 70
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -306.5%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 0.0%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- โ
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.